Skip to main content
. 2025 Feb 11;14:1382017. doi: 10.3389/fcimb.2024.1382017

Table 6.

Personal interpretation of therapeutic options according to liver disease.

Liver disease Contraindication to Peg-IFN Standard therapy
Chronic hepatitis or compensated cirrhosis without esophageal varices no Peg-IFN+Bulevirtide 2mg
for 48 weeks
yes Bulevirtide 2mg
Compensated cirrhosis with esophageal varices Yes Bulevirtide 2mg
Decompensated cirrhosis yes Unknown
Bulevirtide 2 mg is an option